Target Name: CDC40
NCBI ID: G51362
Review Report on CDC40 Target / Biomarker Content of Review Report on CDC40 Target / Biomarker
CDC40
Other Name(s): hPRP17 | pre-mRNA splicing factor 17 | PCH15 | PRP17 | cell division cycle 40 | MGC102802 | PRP17_HUMAN | EHB3 | Pre-mRNA-processing factor 17 | OTTHUMP00000040437 | PRPF17 | Cell division cycle 40 | OTTHUMP00000016996 | Ehb3 | EH-binding protein 3 | FLJ10564 | HPRP17 | OTTHUMP00000016997 | cell division cycle 40 homolog | Cell division cycle 40 homolog | PRP17 homolog | Pre-mRNA splicing factor 17

hPRP17: A Potential Drug Target and Biomarker

hPRP17 (hematopoietic progenitor-derived plasma-17) is a protein that is expressed in the blood cells, including red blood cells, white blood cells, and platelets. It is a hematopoietic stem cell derived protein that plays a crucial role in the development and maintenance of blood cells. The discovery of hPRP17 as a potential drug target and biomarker has significant implications for the field of hematology and regenerative medicine.

CDC40: The hPRP17 Promote the Generation of Blood Cells

CDC40 (Complement component 40) is a transmembrane protein that is expressed in various cell types, including blood cells, neurons, and epithelial cells. It is a key regulator of the immune response and plays a crucial role in the development and maintenance of tissues and organs.

hPRP17 is a potent regulator of CDC40 signaling. It can inhibit the activity of CDC40 and enhance the activity of its downstream effectors, such as PD-L1 and PD-L2. This interaction between hPRP17 and CDC40 has significant implications for the regulation of blood cell development and regeneration.

hPRP17 as a Potential Drug Target

hPRP17 has been identified as a potential drug target due to its critical role in the development and maintenance of blood cells. The inhibition of hPRP17 activity by drugs has been shown to enhance the production of blood cells in bone marrow and improve their quality. This has significant implications for the treatment of anemia, a common condition that affects millions of people worldwide, particularly those undergoing cancer treatment.

hPRP17 as a Biomarker

hPRP17 can also be used as a biomarker for the diagnosis and monitoring of certain hematological conditions, such as myelodysplastic syndromes and myelination disorders. These conditions are characterized by the failure of blood cells to develop or function properly, leading to anemia, infections, and other serious health problems.

hPRP17 levels can be used as a marker for the diagnosis of myelodysplastic syndromes, a type of cancer that affects the development of blood cells. The treatment of myelodysplastic syndromes is often difficult and requires a significant amount of stem cells to restore the patient's health. hPRP17 has been shown to be a sensitive biomarker for the diagnosis and monitoring of myelodysplastic syndromes, with higher levels of hPRP17 indicating a greater risk of disease.

hPRP17 levels can also be used as a marker for the diagnosis and monitoring of myelination disorders, conditions that affect the development and function of the myelin sheath surrounding the blood cells. These disorders are characterized by the failure of myelination to grow and function properly, leading to anemia, infections, and other serious health problems.

Conclusion

hPRP17 is a protein that has significant implications for the field of hematology and regenerative medicine. Its regulation of CDC40 signaling and its potential as a drug target and biomarker make it an attractive target for research into the development of new treatments for anemia and other hematological conditions. Further studies are needed to fully understand the role of hPRP17 in the development and maintenance of blood cells and its potential as a drug and biomarker.

Protein Name: Cell Division Cycle 40

Functions: Required for pre-mRNA splicing as component of the activated spliceosome (PubMed:33220177). Plays an important role in embryonic brain development; this function does not require proline isomerization (PubMed:33220177)

The "CDC40 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC40 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B